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ated with either disease recurrence or cancer-specific death 
regardless of pathologic stage. The presence of concomitant 
CIS did not improve the predictive accuracy of standard pre-
dictors for either disease recurrence or cancer-specific death 
in any of the subgroups. Conclusions: We could not confirm 
the prognostic value of concomitant CIS in RC specimens. 
This, together with the discrepancy between pathologists in 
determining the presence of concomitant CIS at the mor-
phologic level, limits the clinical utility of concomitant CIS in 
RC specimens for clinical decision-making.
Copyright © 2011 S. Karger AG, Basel
Introduction
Bladder cancer is the second most common malignan-
cy of the genitourinary system [1]. Carcinoma in situ 
(CIS) is a potentially aggressive cancer diathesis of the 
bladder with varied clinical behavior. Historically, up to 
83% of patients diagnosed with CIS in the absence of 
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Abstract
Objective: The aim of this study was to externally validate 
the prognostic value of concomitant urothelial carcinoma in 
situ (CIS) in radical cystectomy (RC) specimens using a large 
international cohort of bladder cancer patients. Methods: 
The records of 3,973 patients treated with RC and bilateral 
lymphadenectomy for urothelial carcinoma of the bladder 
(UCB) at nine centers worldwide were reviewed. Surgical 
specimens were evaluated by a genitourinary pathologist at 
each center. Uni- and multivariable Cox regression models 
addressed time to recurrence and cancer-specific mortality 
after RC. Results: 1,741 (43.8%) patients had concomitant CIS 
in their RC specimens. Concomitant CIS was more common 
in organ-confined UCB and was associated with lymphovas-
cular invasion (p ! 0.001). Concomitant CIS was not associ-
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muscle-invasive urothelial carcinoma of the bladder 
(UCB) went on to develop invasive carcinoma if left un-
treated, and up to 39% died of their disease [2, 3]. UCB 
CIS spreads along the surface of the bladder focally or in 
a diffuse pattern and can be difficult to diagnose. Patients 
presenting with isolated or concomitant CIS lesion are at 
high risk of experiencing disease progression to muscle-
invasive UCB [4–7]. Moreover, presence of CIS is a strong 
predictor of UCB spread to the upper urinary tract [8–10] 
and the prostatic urethra [11].
We have previously shown that concomitant CIS in 
radical cystectomy (RC) specimens is relatively com-
mon, and patients with organ-confined UCB and con-
comitant CIS are at increased risk of disease recurrence 
and eventual death [5]. Before use in daily clinical deci-
sion-making, the prognostic value of concomitant CIS 
needs to be externally validated in large, multicenter da-
tasets. Moreover, the question of whether concomitant 
CIS can improve the ability of established predictors of 
cancer outcome requires more than the conventional 
uni- and multivariable analyses with associated hazard 
rates and p values. In order for concomitant CIS to be 
clinically useful, it must add unique predictive informa-
tion, thus improving the performance of a predictive 
model constructed without concomitant CIS by a sig-
nificant margin [12, 13]. Therefore, we sought to exter-
nally validate our previous findings in a large external, 
independent international cohort of patients treated 
with RC for UCB. We tested the hypothesis that concom-
itant CIS in the RC specimens could improve the accu-
racy of predictive models that include standard histo-
pathologic features for prediction of stage-specific dis-
ease recurrence and survival in patients treated with RC 
for UCB.
Patients and Methods
Patient Selection and Data Collection
This was an institutional review board approved study with 
all participating sites providing the necessary institutional data 
sharing agreements prior to initiation of the study. A total of nine 
centers worldwide provided data. This study comprised 3,973 pa-
tients who underwent RC with bilateral lymphadenectomy be-
tween 1979 and 2008. Patients who received preoperative radio-
therapy or chemotherapy were not excluded from the study. No 
patient had distant metastatic disease at the time of RC. None of 
the patients received adjuvant radiotherapy. Overall, 974 patients 
(24.5%) received adjuvant chemotherapy at the investigator’s dis-
cretion based on patient tumor stage and overall medical status.
A computerized databank was generated for data transfer. Af-
ter combining the datasets, reports were generated for each vari-
able to identify data inconsistencies and other data integrity prob-
lems. Through regular communication with all sites, resolution 
of all identified anomalies was achieved before analysis. Prior to 
final analysis, the database was frozen and the final dataset was 
produced for the current analysis.
Pathologic Evaluation
All surgical specimens were processed according to standard 
pathologic procedures, and all slides were evaluated by genitouri-
nary pathologists according 1993 WHO grading and 2002 AJCC 
TNM staging. The presence of concomitant CIS was defined as 
the presence of CIS in conjunction with another pathologic T 
stage other than CIS alone. Pelvic lymph node dissections were 
examined grossly and all lymphoid tissue was submitted for his-
tological examination. Lymphovascular invasion (LVI) was de-
fined as the unequivocal presence of tumor cells within an endo-
thelium-lined space without underlying muscular walls.
Follow-Up
Follow-up was performed according to institutional protocols. 
Patients were generally seen postoperatively at least every 3–4 
months for the first year, semi-annually for the second year, and 
annually thereafter. Follow-up visits consisted of a physical ex-
amination and serum chemistry evaluation. Diagnostic imaging 
of the upper tracts (e.g., ultrasonography and/or intravenous py-
elography, CT abdomen/pelvis with IV contrast) and chest radi-
ography were performed at least annually or when clinically indi-
cated. Additional radiographic evaluation, such as bone scan and/
or computerized tomography, was performed at the discretion of 
the treating physician. Detection of cancer in the ureter and/or 
urethra was coded as a second (metachronous) primary and not 
as local or distant recurrence. When patients died, the cause of 
death was determined by the treating physicians, by chart review 
corroborated by death certificates, or by death certificates alone. 
Patients who were identified as having died of bladder cancer had 
progressive, widely disseminated, and often highly symptomatic 
metastases at the time of death. Perioperative mortality (death 
within 30 days of surgery) was censored at the time of death for 
bladder cancer-specific survival analyses.
Statistical Analysis
Fisher’s exact test and the x2 test were used to evaluate the as-
sociation between categorical variables. Differences in variables 
with a continuous distribution across dichotomous categories 
were assessed using the Mann-Whitney U test. The Kaplan-Meier 
method was used to calculate survival functions, and differences 
were assessed with the log-rank statistic. Uni- and multivariable 
Cox regression models addressed time to recurrence and cancer-
specific mortality after RC. In all models, proportional hazards 
assumptions were systematically verified using the Grambsch-
Therneau residual-based test. Since a proportion of patients treat-
ed with RC for invasive UCB die of other causes than UCB, com-
peting risk regression was used to test the significance of variables 
after accounting for other-cause mortality [14]. The change in 
predictive accuracy (PA) was quantified with Harrell’s concor-
dance index [15, 16]. 200-bootstrap resampling was used to adjust 
for overestimation [15, 16]. All reported p values are two-sided, 
and statistical significance was set at p ! 0.05. All statistical tests 
were performed with S-Plus Professional (MathSoft Inc., Seattle, 
Wash. USA).
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Results
Association of Concomitant CIS with 
Clinicopathologic Characteristics
The association of concomitant CIS with clinicopath-
ologic characteristics is shown in table 1. Of the 3,973 pa-
tients, 1,741 (43.8%) had concomitant CIS in the RC spec-
imens. Within pathologic stages, the proportion of con-
comitant CIS decreased in order from patients with pT1 
UCB, to pT2 UCB, to pT4 UCB, to pT3 UCB, and finally 
to pTa UCB. Patients with pathologic grades II and III 
were more likely to have concomitant CIS than patients 
with pathologic grade I (p ! 0.001). There was no differ-
ence in the rate of concomitant CIS between patients with 
pathologically non-muscle-invasive versus muscle-inva-
sive UCB (p = 1.000) and between those with pathologi-
cally non-organ-confined versus organ-confined UCB 
(p = 0.062). Patients with LVI were more likely to exhibit 
concomitant CIS than those without LVI (p ! 0.001).
Association of Concomitant CIS in RC Specimens with 
Clinical Outcomes
Disease recurrence occurred in 1,421 of 3,973 patients 
(35.8%); 1,928 patients (48.5%) were deceased at the time 
Table 1. Association of concomitant CIS with clinical and pathologic characteristics in 3,973 patients treated with RC and bilateral 
lymphadenectomy
Concomitant CIS p
negative 
(n = 2,232, 56.2%)
positive 
(n = 1,741, 43.8%)
Age, years (median, range) 67.0 (23.3–94.2) 67.0 (29.7–93.9) 67.1 (23.4–94.2) 0.230
Number of lymph nodes removed
(median, range)
18 (0–214) 16 (0–122) 20 (0–14) <0.001
Gendera
Female 802 (20.2) 469 (58.5) 333 (41.5)
Male 3,154 (79.3) 1,745 (55.4) 1,407 (44.6) 0.120
Pathologic stage a
pT0 (no tumor) 228 (5.7) 228 (100.0) 0 (0.0)
pTa 129 (3.2) 95 (73.6) 34 (26.4)
pT1 597 (15.0) 211 (35.3) 386 (64.7)
pT2 1,063 (26.8) 564 (53.1) 499 (46.9)
pT3 1,384 (34.8) 822 (59.4) 562 (40.6)
pT4 572 (14.4) 312 (54.5) 260 (45.5) <0.001
Pathologic grade a
0 (no tumor) 228 (5.7) 228 (100.0) 0 (0.0)
Low 78 (2.0) 53 (67.9) 25 (32.1)
High 3,667 (92.3) 1,951 (53.2) 1,716 (46.8) <0.001
Lymphovascular invasion a
Absent 2,400 (60.4) 1,426 (59.4) 974 (40.6)
Present 1,403 (35.3) 732 (52.2) 671 (47.8) <0.001
Soft tissue surgical margin status a
Absent 3,678 (92.6) 2,079 (56.5) 1,599 (43.5)
Present 276 (6.9) 139 (50.4) 137 (49.6) 0.051
Adjuvant chemotherapy a
Absent 2,997 (75.4) 1,710 (57.1) 1,287 (42.9)
Present 974 (24.5) 521 (53.5) 453 (46.5) 0.053
Metastasis to lymph nodes a
Absent 2,814 (70.8) 1,595 (56.7) 1,219 (43.3)
Present 1,105 (27.8) 592 (53.6) 513 (46.4) 0.080
a Figures are number of patients with percentage in parentheses.
Gender was missing in 19 patients (0.5%). Soft tissue surgical margin status was missing in 19 patients (0.5%). Lymphovascular in-
vasion was missing in 170 patients (4.3%). Metastasis to lymph nodes was missing in 54 patients (1.4%). Adjuvant chemotherapy was 
missing in 2 patients (0.1%)
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of analysis; 1,180 patients (29.7%) died of bladder cancer. 
The median follow-up was 45 months for patients alive at 
last follow-up (mean 8 SD: 66.1 8 63.6, interquartile 
range: 67). Actuarial recurrence-free survival estimates 
were 60% (standard error (SE): 1) at 3 years, 57% (SE: 1) 
at 5 years, and 54% (SE: 1) at 10 years after RC. Actuarial 
cancer-specific survival estimates were 67% (SE: 1) at 3 
years, 62% (SE: 1) at 5 years, and 58% (SE: 1) at 10 years 
after RC.
In univariable analyses, there was no difference in dis-
ease recurrence or cancer-specific survival between pa-
tients with or without concomitant CIS (p = 0.094 and 
p = 0.058, respectively). We evaluated the association of 
concomitant CIS with bladder cancer recurrence and 
survival within each pathologic stage (table 2). There was 
no difference in disease recurrence or cancer-specific 
survival between patients with or without concomitant 
CIS in patients with pT1, pT2, pT4, organ-confined dis-
ease, non-organ-confined disease, non-muscle-invasive 
or muscle-invasive UCB (all p values 10.05).
In patients with pT3 disease, patients with concomi-
tant CIS were at increased risk of disease recurrence and 
cancer-specific death compared to those without con-
comitant CIS (p = 0.018 and p = 0.003, respectively). Con-
comitant CIS did not retain its statistical significance 
when adjusted for the effects of pathologic grade, surgical 
margin status, LVI, and lymph node metastasis (p = 0.157 
for disease recurrence and p = 0.089 for cancer-specific 
death).
In univariable analyses, concomitant CIS was not sig-
nificantly associated with disease recurrence (HR 1.1; p = 
0.094) and death (HR 1.1; p = 0.058). The PA of concom-
itant CIS for disease recurrence was 51.4% in both all pa-
tients and organ-confined patients. The PA of concomi-
tant CIS for cancer-specific death was 51% in all patients 
and 50.2% in organ-confined patients. In multivariable 
Table 2. Pathologic stage-specific recurrence-free and cancer-specific survival estimates according to concomitant CIS in 3,973 pa-
tients treated with RC and bilateral lymphadenectomy
Presence of
concomitant CIS
Probability of disease recurrence, % Probability of cancer-specific survival, %
3-year 8 SE 5-year 8 SE 10-year 8 SE p 3-year 8 SE 5-year 8 SE 10-year 8 SE p
pT1
Negative 7883 7883 7584 8383 8084 8084
Positive 8282 7783 7383 0.704 8882 8483 7883 0.989
pT2
Negative 7282 6883 6483 7882 7283 6883
Positive 7083 6683 6683 0.918 7783 7283 7083 0.845
pT3
Negative 5182 4882 4782 5882 5382 5083
Positive 4283 3883 3883 0.018 4883 4283 3883 0.003
pT4
Negative 3283 2983 2784 4184 3484 3184
Positive 3584 3384 3384 0.390 4284 3884 3784 0.973
All patients
Negative 6181 5981 5681 6881 6481 6081
Positive 5881 5481 5281 0.094 6581 6081 5682 0.058
Pathologic non-muscle-invasive stage (<pT2)
Negative 8782 8482 8183 9182 8882 8782
Positive 8682 8282 7782 0.614 9281 8782 8382 0.425
Pathologic muscle-invasive stage (≥pT2)
Negative 5482 5182 4882 6182 5682 5282
Positive 5182 4882 4782 0.452 5782 5282 5082 0.155
Pathologic organ-confined stage (<pT3)
Negative 8182 7882 7582 8781 8282 7982
Positive 8281 7982 7682 0.571 8881 8481 8082 0.683
Pathologic non-organ-confined stage (≥pT3)
Negative 4682 4382 4282 5482 4982 4582
Positive 4182 3782 3782 0.135 4882 4282 3982 0.052
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analyses, concomitant CIS was not associated with dis-
ease recurrence (HR 0.99; p = 0.960) or death (HR 0.99; 
p = 0.833) when adjusted for the effects of standard patho-
logic features (table 3). Addition of concomitant CIS to 
multivariable models that included standard pathologic 
features improved its PA by 0.1% for disease recurrence 
and 0% for cancer-specific death. In patients with organ-
confined disease, addition of concomitant CIS to multi-
variable models that included standard pathologic fea-
tures (pathologic stage, grade, and LVI) improved its PA 
by 0.1% for disease recurrence and 0.2% for cancer-spe-
cific death.
Discussion
Urothelial CIS is likely the most common precursor of 
invasive UCB [17–19]. Several cytogenetic [17, 20] molec-
ular genetic [21] and immunohistologic [22–25] studies 
have shown similar molecular alterations for CIS and 
muscle-invasive UCB. Several small studies have shown 
that the presence of concomitant CIS in patients with 
papillary, non-muscle-invasive UCB is associated with 
significantly worse clinical outcome after RC [26–28]. In 
patients with clinical stage T1 grade 3 UCB treated with 
RC, concomitant CIS was the only pre-cystectomy factor 
associated with disease recurrence and mortality in 171 
patients treated with RC [7]. The risk of disease recur-
rence increased 2.5-fold and the risk of bladder cancer-
specific death increased 3-fold when concomitant CIS 
was identified preoperatively. Similarly, Masood et al. 
[26] reported that T1 grade 3 UCB patients with concom-
itant CIS have a higher probability of disease progression 
than those without concomitant CIS (55 vs. 6%). More-
over, two studies have also shown that CIS is an indepen-
dent predictor of disease progression to muscle-invasive 
UCB [29, 30]. Sylvester et al. [30] studied 2,596 patients 
with Ta and T1 bladder cancer enrolled in EORTC clini-
cal trials and found a 3.4-fold risk of progression to mus-
cle-invasive disease among patients with CIS. Thus, pa-
tients with non-muscle-invasive disease with CIS are at a 
high risk of progression to muscle invasion and also have 
a worse prognosis after RC. This has led many clinicians 
to follow CIS-only patients closely and consider them for 
early RC. 
The prognostic value of concomitant CIS in patients 
with papillary tumors remains unclear to date. Recently, 
in a tri-institutional study of 713 patients treated with RC, 
we found that concomitant CIS is more common in low-
er-stage and higher-grade disease, and is significantly as-
Table 3. Multivariable Cox regression analyses of concomitant CIS for prediction of recurrence and death of disease in 3,973 patients 
treated with RC for UBC (1,421 recurrences and 1,180 cancer-specific deaths)
Predictors Multivariable analysis for disease recurrence Multivariable analysis for cancer-related death
HR 95% CI p value HR 95% CI p value
Age, continuous 1.005 1.000–1.011 0.06 1.015 1.008–1.021 <0.001
Year of surgery 0.192 0.345
1990–1999 vs. 1979–1989 0.924 0.778–1.098 0.368 0.917 0.764–1.100 0.350
2000–2008 vs. 1979–1989 1.031 0.862–1.233 0.737 1.006 0.828–1.223 0.953
Pathologic T stage <0.001 <0.001
pTa vs. pT0 1.486 0.742–2.975 0.263 0.964 0.364–2.552 0.941
pT1 vs. pT0 1.855 1.165–2.954 0.009 1.067 0.412–2.765 0.894
pT2 vs. pT0 2.587 1.672–4.003 <0.001 1.514 0.590–3.890 0.389
pT3 vs. pT0 4.002 2.599–6.163 <0.001 2.526 0.986–6.470 0.054
pT4 vs. pT0 4.973 3.188–7.756 <0.001 3.003 1.169–7.715 0.022
Lymphovascular invasion 1.442 1.273–1.633 <0.001 1.446 1.262–1.656 <0.001
Concomitant CIS 0.997 0.889–1.118 0.960 0.986 0.869–1.120 0.833
Soft tissue surgical margin 1.524 1.267–1.834 <0.001 1.746 1.439–2.118 <0.001
Pathological grade 0.226 0.271
Grade 2 vs. grade 1 1.611 0.834–3.112 0.116 1.867 0.850–4.104 0.120
Grade 3 vs. grade 1 1.703 0.878–3.303 0.368 1.803 0.816–3.983 0.145
Lymph node metastasis 1.783 1.563–2.035 <0.001 2.009 1.739–2.321 <0.001
Number of removed lymph nodes 0.999 0.996–1.002 0.557 1 0.996–1.004 0.989
Number of positive lymph nodes 1.021 1.012–1.030 <0.001 1.024 1.014–1.034 <0.001
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sociated with UCB involvement of the urethra at RC. 
More importantly, the presence of concomitant CIS in 
patients with pathologic non-muscle-invasive UCB treat-
ed with RC was associated with a significantly worse out-
come [5]. However, before inclusion into daily clinical 
decision-making, such findings need to be confirmed in 
a large, multi-institutional, independent dataset. There-
fore, to validate the clinical utility of concomitant CIS in 
RC specimens for indentifying patients at high risk for 
disease recurrence who could benefit from close surveil-
lance or inclusion into a predictive tool that would help 
select patients for adjuvant therapy, we attempted to vali-
date our previous findings in an independent, interna-
tional cohort of almost 4,000 RC patients.
We confirmed that many patients harbor concomitant 
CIS (43.8%) in addition to their papillary UCB in the RC 
specimens. Moreover, concomitant CIS was significantly 
more common in low-stage and high-grade UCB and was 
associated with LVI. While association with features of 
aggressive disease is important, prediction of outcomes 
after RC is more important for the management of UCB 
patients. In this context, differences in clinical outcome 
between patients with and without concomitant CIS 
could not only be related to tumor progression and devel-
opment of metastases due to more aggressive tumor biol-
ogy, but could also be caused by a result of intraluminal 
recurrence on the basis of multifocal disease. We found 
no association between concomitant CIS and clinical 
outcomes after RC in the entire population or in stage 
subgroups. Although the presence of concomitant CIS 
was associated with increased risk of disease recurrence 
and cancer-specific death for patients with pT3 disease, 
this phenomenon did not retain its statistical significance 
when adjusted for the effects of pathologic grade, surgical 
margin status, LVI and lymph node metastasis. Concom-
itant CIS did not add any information beyond standard 
pathologic features for prediction of oncologic outcomes 
after RC. This remained true in single-center analyses 
(no change in PA; data not shown). This lack of prognos-
tic value was seen in standard multivariable and PA anal-
yses. Concomitant CIS, thus, does not add any additional 
information for management of UCB patients and should 
not be used for clinical decision-making.
This study suffers from several limitations. RC was 
performed by various surgeons and specimens were re-
viewed by multiple pathologists. The difficulty and dedi-
cation necessary in determining its presence of concom-
itant CIS at the morphologic level may have resulted in 
differences between pathologists specimens (interob-
server variability). While this variability may be con-
strued as limitations, the role of an external validation is 
to see whether a factor retains its value in different co-
horts of patients representing a real-world scenario. 
While these limitations can be construed as significant, 
the purpose of this study was to reflect a real-world prac-
tice in which multiple pathologists review tissue speci-
mens and their interpretation is used in clinical decision-
making with the patient. Indeed, the large number of pa-
tients and the diversity of centers in expertise, volume, 
and geographical location increase the generalizability of 
the findings.
In this multicenter study, more than half of all patients 
undergoing RC for UCB had concomitant CIS on final 
pathology. Concomitant CIS was more common in or-
gan-confined UCB and high-grade UCB, and concomi-
tant CIS was associated with LVI. However, we could not 
confirm the prognostic value of concomitant CIS in the 
RC specimens for prediction of clinical outcomes. Con-
comitant CIS had no impact on disease recurrence or 
cancer-specific survival in standard Cox regression and 
PA analyses. These data support that CIS concomitant 
with papillary disease in the RC specimens does not add 
any information beyond standard histopathologic fea-
tures and has no clinical utility in the management of 
UCB patients.
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